An Open Label, Phase I Study To Determine the Safety, Tolerability and Pharmacodynamics of Multiple Ascending Doses of PMZ-1620 in healthy male volunteers.

Trial Profile

An Open Label, Phase I Study To Determine the Safety, Tolerability and Pharmacodynamics of Multiple Ascending Doses of PMZ-1620 in healthy male volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs PMZ 1620 (Primary)
  • Indications Cerebrovascular disorders; Neurodegenerative disorders; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pharmazz
  • Most Recent Events

    • 09 Feb 2017 According to a Spectrum Pharmaceuticals media release, first patient has been dosed in the study.
    • 08 Dec 2016 New source identified and integrated Clinical Trials Registry - India : CTRI/2016/11/007509
    • 08 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top